Plate Reader for Automated Characterization of Macromolecules and Nanoparticles
Wyatt Technology has added the DynaPro Plate Reader III to its macromolecular and nanoparticle characterization product offerings.
The DynaPro Plate Reader III from Wyatt Technology is an integrated instrument for automated characterization of size, molecular weight, aggregation, and stability of macromolecules and nanoparticles.
The instrument, which combines both dynamic light scattering and static light scattering approaches, contains a single, fully automated platform with measurements taken directly in 96, 384, or 1536 microwell plates. It can rapidly screen proteins, nanoparticles, colloids, and macromolecules to determine their size, molecular weight, aggregation, and stability profiles using a minimum of 4 μL of sample.
Additionally, the instrument can characterize both conformational and colloidal stability indicators like Tonset, Tagg, A2 and kD by running a temperature ramp or concentration series. Scientists can also perform viscosity determinations for the viability of biopharmaceuticals, and use the built-in camera to image each for additional insight.
Source: Wyatt Technology
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
